All News
RA Biologics Lower COVID-19 Deaths, but Not Recovery Time
Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?
Read Article
Baricitinib Effective in JIA Subsets
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
Read Article
GCA and the Risk of Cerebrovascular Ischemic Events
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
Read Article
JAMA: Prophylaxis for Pneumocystis Pneumonia - indications and Rx
- Immuncompromised and Immunodeficient
- Pts on Hi Dose Steroids
- ANCA–associated vasculitis
https://t.co/2VhLxc4VNo https://t.co/cXuY4Manrk
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: ChatGPT - A Boon or Threat to Scientific Publication?
https://t.co/nt4m6n27A3 https://t.co/oo88u5X86Z
Links:
Dr. John Cush RheumNow ( View Tweet)
GCA and the Risk of Cerebrovascular Ischemic Events
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
https://t.co/MAjgWg71vK https://t.co/UhMtiWf7gh
Links:
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib Outcomes in High Risk RA Patients
A safety analysis of six phase III SELECT trials showed that higher-risk RA patients had an increased risk of MACE, malignancy (excluding NMSC) and VTE regardless of being treated with either UPA or ADA.
https://t.co/7JXntIV09K https://t.co/CthPcu2Ohs
Links:
Dr. John Cush RheumNow ( View Tweet)
A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/NubTu8mGq4 https://t.co/OQSIpHgLyn
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
https://t.co/SLgUKQKbFs https://t.co/xCc2D5Hx8S
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: 25 Great Women in Rheumatology
https://t.co/ghCAUBMMja https://t.co/cr2xI2VrgE
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Carpal Tunnel - Steroid injection vs. Night Splinting
A trial conducted by the UK National Health Service, studied interventions in patients with CTS and found no advantage to either CTS CSI or NS as the initial treatment.
https://t.co/b8yZSKRK2X https://t.co/zOYaYOtuJd
Links:
Dr. John Cush RheumNow ( View Tweet)
Pain is the leading cause of disability worldwide. Chronic pain affects 33-50% of the population. High impact chronic pain is seen in 4.8% of US adult population. Chronic pain accounts for 22-50% of GP consultations. More from BMJ.. https://t.co/IRVpJZNS0L https://t.co/YVIM38aWWK
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review of "Treatments for Lupus Nephritis" from Isenberg et al - discussing:
- Pathogenesis, outcomes
- Conventional Rx
- B cell targeting: BEL, RTX, Obintuzumab, Atacicept & more
- Sequential Rx: Synviose, BEAT, BLISS-Believe
- JAKi & more https://t.co/X0xn9FeL0j https://t.co/Fiyf5Drh93
Links:
Dr. John Cush RheumNow ( View Tweet)
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform.
https://t.co/CeLTCbB2nO https://t.co/qYXt8gCHjd
Links:
Dr. John Cush RheumNow ( View Tweet)
NIH MOST study 2093 OA pts w/ Knee Xrays/CT/Pain scores q8 mos x2 yrs. IA mineralization seen in 10% knees & assoc w/ a 2 fold higher risk of freq knee pain & OR 1.86 of freq intermit/constant pain. IA mineralz. meniscus or Jt capsule=higher odds of pain https://t.co/CacJ40DVyL https://t.co/Zhwv98d6Pe
Links:
Dr. John Cush RheumNow ( View Tweet)
Since the end of COVID, how often do you see Pharma Sales Reps (PSRs)?
Dr. John Cush RheumNow ( View Tweet)
Scleroderma – Thick and Thin
This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.
https://t.co/IF5c8MF1zk https://t.co/zhwR4SofHt
Links:
Dr. John Cush RheumNow ( View Tweet)
In Memoriam: Dr. K. Frank Austen (1928-2023)
Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95.
https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R
Links:
Dr. John Cush RheumNow ( View Tweet)
Scary Outcomes with Systemic Sclerosis Sine Scleroderma
The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc.
https://t.co/WwwmDxt5DL https://t.co/iXepaWvoCY
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioids Ineffective in Acute Lower Back and Neck Pain
A randomised controlled trial including 347 participants with lower back or neck pain found there was no benefit of taking opioid pain relievers compared to placebo.
https://t.co/96mETyhKyL https://t.co/48ojNCnoZW
Links:
Dr. John Cush RheumNow ( View Tweet)